Yahoo · Nov 9, 2026
Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
Publication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease Initially presented at AAN, the primary analysis measured at 16 weeks demonstrated statistically significant improvements across all primary and secondary endpoints, including mobility and disability, with patients no longer requiring chronic immunotherapi

